CPRX Catalyst Corp: רווח למניה בשנים עשר החודשים האחרונים

Catalyst Pharmaceuticals relies on outsourced manufacturing, depending on external suppliers. Exclusive rights to orphan drugs facilitate easy sales expansion with minimal costs, while environmental impact is limited to partner audits. The annual EPS growth based on financial reporting (TTM) illustrates the earnings per share trend, where the current metric equals 9.60.

This indicator measures the dynamics of earnings per share over the last twelve months relative to the same period last year, reflecting the efficiency of capital generation. For Catalyst Pharmaceuticals (CPRX), the comparable year-over-year growth in EPS TTM confirms high business margins driven by exclusive rights to orphan drugs and a lack of competition in the rare disease segment.